Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other financing activities (2020 - 2022)

UroGen Pharma (URGN) has disclosed Other financing activities for 3 consecutive years, with $16000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Other financing activities fell 86.21% year-over-year to $16000.0, compared with a TTM value of $16000.0 through Jun 2023, down 94.22%, and an annual FY2022 reading of $160000.0, up 11.11% over the prior year.
  • Other financing activities was $16000.0 for Q3 2022 at UroGen Pharma, down from $55000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $203000.0 in Q1 2020 and bottomed at $11000.0 in Q4 2020.
  • Average Other financing activities over 3 years is $64750.0, with a median of $36000.0 recorded in 2021.
  • Peak annual rise in Other financing activities hit 400.0% in 2022, while the deepest fall reached 86.21% in 2022.
  • Year by year, Other financing activities stood at $11000.0 in 2020, then skyrocketed by 54.55% to $17000.0 in 2021, then decreased by 5.88% to $16000.0 in 2022.
  • Business Quant data shows Other financing activities for URGN at $16000.0 in Q3 2022, $55000.0 in Q2 2022, and $89000.0 in Q1 2022.